January 6, 2014 – In its latest web-based edition of EHJ TODAY INTERVIEWS, the European Heart Journal published by Oxford University Press features an interview with Douglas L. Mann, MD, Professor and Chief, Cardiovascular Division of Washington University School of Medicine, and Jean-Sebastien Hulot, MD, Assistant Professor Medicine, Cardiology, at The Mount Sinai Hospital in New York City. The moderator is Stefanie Dimmeler, MD, Ph.D., Professor of Cardiology at the Goethe University in Frankfurt, Germany.
Targeted primarily at physicians, the EHJ TODAY video session provides a brief summary and assessment of the interim results of the multicenter, randomized AUGMENT-HF clinical trial showing left ventricle augmentation of the failing heart with the Algisyl-LVR® hydrogel implant. The results were presented on November 20, 2013 by Dr. Mann and discussed by Dr. Hulot at the late-breaking clinical trials session of the American Heart Association annual meeting held at the Dallas Convention Center.
To watch the video on the website of the European Heart Journal, please follow the link below:
Classified by the U.S. Food and Drug Administration as a medical device, Algisyl-LVR is intended to reverse HF progression in patients who have an enlarged left ventricle. The product consists of a proprietary hydrogel that is injected directly into strategic areas of the dilated left ventricle muscle in a surgical procedure lasting approximately 75 minutes. Performing the function of a prosthetic scaffold, the hydrogel acts immediately and does not undergo long-term degradation. Extensive preclinical studies have shown Algisyl-LVR decreases cardiac wall tension, while it improves heart muscle contractility and oxygen uptake, leading to a decrease in ventricle stress and to a marked cardiomechanic improvement. The safety and efficacy of Algisyl-LVR® are being evaluated in clinical trials in Europe and Australia. The product is not available for sale.
Advanced Heart Failure:
Advanced HF represents a significant and growing epidemic healthcare burden in all developed countries. Of the more than 12 million patients affected in the North America and in Western Europe, about a third have significant limitations of physical activity while half die of heart failure within five years of diagnosis. A wide number of patients whose heart muscle is initially damaged by infarcts, hypertension, valve disease, or other processes lose the ability to pump blood efficiently to the body. To overcome the initial damage, the heart muscle works under increased stress without an opportunity to recover. Eventually, the muscle of the left ventricle begins to stretch out and the muscle cells lose the ability to contract normally. The therapeutic options for many of these patients who do not respond to drug and device therapies are limited and can be extremely complex and costly.
LoneStar Heart Inc.:
LoneStar Heart, Inc., based in Laguna Hills, Calif., is developing cardiac restorative therapies for patients with heart failure that harness the heart’s ability to repair itself. Based on its integrated cardiomechanical and biomolecular technologies, the privately held company is advancing a broad portfolio of products to restore the failing heart’s structure and function in collaboration with the Texas Heart Institute, the University of Texas Southwestern Medical Center, and a global network of leading clinicians. These products include Algisyl-LVR, cardiac stem-cell modulators, and cellular and genetic therapies delivered as stand-alone treatments, or in combination with the company’s proprietary biopolymer matrix system.
For more information, contact firstname.lastname@example.org